FDA Approves First Generic Lenacapavir for HIV Prevention

Dr Reddy's Laboratories' generic version of the twice-yearly injection is licensed for sale in 120 resource-limited countries under a Gilead agreement.

Updated on Nov. 17, 2026 in Sexual Health

Flat-color editorial illustration of a single glass injectable vial beside a plain shipping crate, set against a solid navy background.
Dr Reddy's Laboratories received FDA approval for the first generic lenacapavir, a twice-yearly HIV-prevention injection licensed for sale in 120 countries. AI Illustration. Upload story photo >

Live Poll

Do you think cheaper generic medicines will make HIV prevention easier to get?

The FDA has approved the first generic version of lenacapavir, a twice-yearly injection used to prevent HIV, developed by Dr Reddy's Laboratories. Dr Reddy's plans to sell the generic in 120 high-incidence, resource-limited countries under a non-exclusive, royalty-free licensing agreement with Gilead.

Why it matters

The approval arrives about 16 months after the originator product was approved, and it targets regions where access to HIV prevention has been limited by cost. Supplies are expected to reach countries by the end of the year, with the generic projected to cost $40 for two annual injections.

The generic was approved roughly 16 months after the originator product, and it is projected to cost $40 for two annual injections across 120 designated countries. Exact distribution timing by country has not been specified.

The players

Dr Reddy's Laboratories

An Indian multinational pharmaceutical company headquartered in Hyderabad that manufactures generic medicines for markets worldwide.

Gilead Sciences

A U.S. biopharmaceutical company that developed lenacapavir and licensed the generic manufacturing rights to Dr Reddy's.

The details

Dr Reddy's developed the generic version with financial, technical, and regulatory support from global health partners, including Unitaid, Wits RHI, and the Clinton Health Access Initiative (CHAI). More than 125,000 people in Africa have already started on lenacapavir.

Timeline

  1. October 2024: Gilead and Dr Reddy's signed the licensing agreement.

  2. 02/11/2026: FDA approval of the generic lenacapavir was reported.

  3. End of 2026: Generic supplies are expected to reach countries.

Market Landscape

This approval follows the non-exclusive, royalty-free voluntary license Gilead granted to Dr Reddy's in October 2024, a model that enables generic production of an HIV prevention injection in restricted markets. The generic's arrival extends that licensing approach from the originator product into a lower-cost alternative.

The projected $40 price for two annual injections could make twice-yearly HIV prevention accessible in countries where the originator product has been out of reach. Individuals in the designated 120 countries may see the generic become available through health programs by the end of the year.

The takeaway

A lower-cost generic can widen access to HIV prevention in regions where the originator injection has been hard to afford. Readers in covered countries should watch for local health program announcements as supplies arrive.

What happens next

Generic lenacapavir supplies are expected to reach countries by the end of 2026.

Further reading

For more background on HIV prevention options, see Sexual Health.

Source note: This article includes information reported by fundsforNGOs News - Grants and Resources for Sustainability.

Live Poll

Do you think cheaper generic medicines will make HIV prevention easier to get?